Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Robert Van Nostrand, vice president of finance and administration at ONCS, said the chemoprotectant agent will enter the
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury